Acute Agitation and Aggression Treatment Market Research Report: Information by Drug Class (First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Indication (Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-induced Agitation and Aggression, Alcohol Withdrawal, and Others), by End User (Hospitals & Clinics, Psychiatric Care Facilities, and Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—For

Global Acute Agitation and Aggression Treatment Market Overview

Acute Agitation and Aggression Treatment Market size was valued at USD 5.52 billion in 2022. The acute agitation and aggression treatment market industry is projected to grow from USD 5.82 billion in 2023 to USD 9.40 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.95% during the forecast period (2023 - 2032). The rising prevalence of acute agitation and aggression and the increase in focus on creating awareness about agitation and aggression are driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

April 2022: BioXcel Therapeutics, Inc., a biopharmaceutical company that uses artificial intelligence (AI) techniques to discover and create groundbreaking medicines in neuroscience and immuno-oncology, has received approval from the U.S. Food and Drug Administration (FDA) for IGALMI™ (dexmedetomidine) sublingual film. This film is intended for the immediate treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults.1 Patients can self-administer IGALMI under the guidance of a healthcare provider.

Acute Agitation and Aggression Treatment Market Trends

• The rising prevalence of acute agitation and aggression boosts the market growth.

Acute agitation is a state of high anxiety, intense arousal, and high motor activity that can arise from several psychiatric and medical conditions such as anxiety, dementia, and insomnia. The rising prevalence of acute agitation and aggression demands the discovery of newer and more effective drugs for their treatment. Moreover, the growing incidence of schizophrenia, dementia, depression, bipolar disorder, drug-induced agitation, and other mental illnesses is anticipated to fuel the market growth during the forecast period. For instance, according to the National Institute of Mental Health (US), in 2020, serious mental illness (SM)I was expected to affect 14.2 million adults in the US aged 18 and above. Females had a higher prevalence of SMI (7.0%) than males (4.2%). Stress, workplace stress, depression, endocrine disorders, electrolyte imbalance, and other factors are the major causes of acute agitation and aggression.

Furthermore, according to the World Health Organization (WHO), dementia currently affects approximately 10 million people in Europe, with the prevalence expected to double by 2030. Hence, the increasing prevalence of acute agitation and rising burden of psychological illness & mortality will drive the market growth during the forecast period.

Acute Agitation and Aggression Treatment Market Segment Insights

Acute Agitation and Aggression Treatment Drug Class Insights

The Acute Agitation and Aggression Treatment Market segmentation, based on drug class, includes first-generation anti-psychotics, second-generation anti-psychotics, benzodiazepines, and others. The second-generation antipsychotics (SGA) segment is to hold the majority share in 2022 in the Acute Agitation and Aggression Treatment Market revenue. This is due to the effective medication giving the best results for patients suffering from agitation and aggression, and other related disorders. Moreover, second-generation antipsychotics (SGA), also called atypical antipsychotics, are commonly used in the acute setting. Furthermore, SGAs are also used in children with severe autism exhibiting behavioral disturbances though repeatedly giving antipsychotics is not preferred.

September 2021:Otsuka Holdings Co., Ltd (Japan) announced a worldwide collaboration and license agreement with Sumitomo Dainippon Pharma (Japan) for four psychiatry and neurology compounds development codes, including SEP-363856（ulotaront), SEP-4199, SEP-378614, and SEP-380135, which is further augmenting the market growth.

Acute Agitation and Aggression Treatment Route of Administration Insights

The Acute Agitation and Aggression Treatment Market segmentation is based on a route of administration, that includes oral, intramuscular, and others. The oral segment has dominated the market in 2022 and the others segment is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the rising use of agitation treatment drugs in oral form. In addition, orally administered medication are easier route of administration for patients and is preferred as it offers a greater sense of control to patients.

Figure 2: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Acute Agitation and Aggression Treatment Indication Insights

The Acute Agitation and Aggression Treatment Market segmentation, based on indication, includes schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation and aggression, alcohol withdrawal, and others. The dementia segment is to hold the majority share in 2022 in the Acute Agitation and Aggression Treatment Market revenue. This is due to the increase in the incidences of dementia among the geriatric population, the rise in the burden of mental illness, a surge in agitation in patients, and a rise in prescriptions of anti-psychotics. According to the Centers for Disease Control and Prevention, dementia is not a particular disease but is rather a general term for the reduced ability to remember, think, or make choices that interfere with everyday activities. Moreover, it only affects older adults over the age of 65.

Acute Agitation and Aggression Treatment End User Insights

The Acute Agitation and Aggression Treatment Market segmentation is based on the end user that includes hospitals & clinics, psychiatric care facilities, and others. The hospitals & clinics segment has dominated the market in 2022 and psychiatric care facilities is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the rise in the geriatric population, and the increasing number of hospitals. Today most large general hospitals have a psychiatric unit. Most hospitals have adult mental health, old age, and learning disability link psychiatry teams. If needed, they are ready to attend to crises immediately. The hospital stay of many persons with chronic mental illness has been shortened by modern medication and better understanding on the part of the public.

February 2021:Sapravato (Esketamine Nasal Spray) received Johnson & Johnson Services, Inc’s (US) authorization in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder.

Acute Agitation and Aggression Treatment Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American acute agitation and aggression treatment market accounted for the largest market share in 2022. This is attributed to the growing focus on spreading awareness among people regarding treatment associated with agitation and aggression, well-established healthcare infrastructure, the rise in the economic burden of mental illness, presence of leading market players in the region. Additionally, the rise in the focus of players on research and development in the region is also expected to increase demand for acute agitation and aggression treatment across North America.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil

Figure 3: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET BY REGION 2022 & 2032

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe acute agitation and aggression treatment market is expected to account for the second-largest market share due to the increasing prevalence of various health disorders such as dementia, alcohol dependence, depression, and bipolar disorders in the region. Further, the Germany acute agitation and aggression treatment market was attributed to holding the largest market share, and the UK acute agitation and aggression treatment market is expected to fastest-growing market in the European region.

The Asia-Pacific acute agitation and aggression treatment market is expected to grow at the fastest rate from 2023 to 2032. This is due to the rise in the geriatric population and increase in agitation in patients, and ongoing research on the development of novel treatments for agitation in the region. Moreover, China’s acute agitation and aggression treatment market is expected to hold the largest market share, and India acute agitation and aggression treatment market is expected fastest-growing market in the Asia-Pacific region.

Furthermore, rise in the prevalence of mental illnesses such as schizophrenia and bipolar disorder, and the focus of market players on India and Japan to exploit opportunities in these emerging markets. will accelerate growth in the acute agitation and aggression treatment market.

The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of acute agitation and aggression treatment in the Middle East and Africa are the increase in agitation in patients, an increase in focus on creating awareness about agitation and aggression, and ongoing research on the development that boost the market growth in the Middle East. On the other hand, the growth opportunities in developing countries such as South Africa, UAE, and Saudi Arabia are estimated to provide lucrative growth opportunities to the market players.

Acute Agitation and Aggression Treatment Key Market Players & Competitive Insights

The Acute Agitation and Aggression Treatment Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Eli Lilly and Company (US), Pfizer Inc (US), GlaxoSmithKline plc (UK), and Teva Pharmaceutical Industries Ltd (Israel) dominate the Acute Agitation and Aggression Treatment Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the global acute agitation and aggression treatment industry to benefit clients and expand the acute agitation and aggression treatment market sector is to manufacture locally to reduce operating costs.

GlaxoSmithKline is engaged in R&D and manufacturing innovative pharmaceutical medicine, vaccines, and consumer healthcare products across the globe. It operates through four segments, namely, pharmaceuticals, pharmaceuticals R&D, vaccines, and consumer healthcare. Its pharmaceutical segment offers innovative and well-established medicines in respiratory, human immunodeficiency virus (HIV), including lupus, psychiatry, neurology, urology, & anti-infectives, immunoinflamation, and oncology.

Its vaccine segment includes pneumococcal disease, meningitis, hepatitis, rotavirus, whooping, cough, and influenza. The company has a significant global presence in more than 150 countries, including 87 manufacturing sites in 36 countries and large R&D centers in the UK, US, Spain, Belgium, and China. For instance, in July 2021, GlaxoSmithKline plc (UK) collaborated with Alector (US) to co-develop progranulin-elevating monoclonal antibodies, AL001, and AL101, to treat neurodegenerative disorders. This helped the company to retain exclusive commercialization rights outside the US.

Also, Teva Pharmaceutical Industries Ltd (Israel) is one of the leaders in pharmaceutical industries engaged in developing and providing services in generic medicines. The company has more than 1,800 molecules used to create an extensive variety of generic products in almost every therapeutic area. It is specialized in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women’s health, and biologics. It operates in the following regions–North America, Latin America, Europe, Japan, and South Korea. It has 26 FDA-approved plants, and 31 European Medicines Agency (EMA) approved plants worldwide.

Key Companies in the Acute Agitation and Aggression Treatment Market include

• Eli Lilly and Company (US)


• Pfizer Inc (US)


• GlaxoSmithKline plc (UK)


• Teva Pharmaceutical Industries Ltd (Israel)


• Otsuka Holdings Co., Ltd (Japan)


• VIATRIS INC (US)


• Johnson & Johnson Services, Inc (US)


• Novartis AG (Switzerland)


• Lundbeck A/S (Denmark)


• Amneal Pharmaceuticals LLC (US)

Acute Agitation and Aggression Treatment Industry Developments

November 2021:The European Commission approved Johnson & Johnson Services, Inc (US) authorization to use (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults.

September 2021:Johnson & Johnson Services, Inc. (US) received FDA approval for INVEGA HAFYERA (6-month paliperidone palmitate), the first and only biennial treatment for schizophrenia.

August 2021:Teva Pharmaceutical Industries Ltd (Israel) And MedinCell (France) announced the acceptance of a new drug application (NDA) by US-FDA for the TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia. This has significantly augmented the growth of the company.

December 2020:GlaxoSmithKline plc (UK) collaborated and signed an agreement with Ligand Pharmaceuticals’(US) subsidiary Icagen (US) to develop small molecule therapeutics for neurological diseases via company discovery technology. This collaboration further opened new opportunities to grow faster in the market.

Acute Agitation and Aggression Treatment Market Segmentation

Acute Agitation and Aggression Treatment Drug Class Outlook

• First-Generation Anti-Psychotics


• Second-Generation Anti-Psychotics


• Benzodiazepines


• Others

Acute Agitation and Aggression Treatment Route of Administration Outlook

• Oral


• Intramuscular


• Others

Acute Agitation and Aggression Treatment Indication Outlook

• Schizophrenia


• Dementia


• Bipolar Disorder


• Depression


• Drug-induced Agitation and Aggression


• Alcohol Withdrawal


• Others

Acute Agitation and Aggression Treatment End User Outlook

• Hospitals & Clinics


• Psychiatric Care Facilities


• Others

Acute Agitation and Aggression Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America